论文部分内容阅读
目的探讨三维适形放射治疗(3DCRT)同步奥利沙铂(L-OHP)化疗治疗晚期局限性非小细胞肺癌(NSCLC)的临床疗效。方法将入选的90例局限性NSCLC患者随机单盲分为A组(47例)和B组(43例),B组患者给予3DCRT放射治疗方案,A组患者在此基础上同步给予L-OHP化疗,对比两组患者治疗后临床疗效和不良反应。结果 (1)A组患者完全缓解率(10.6%)和总有效率(78.7%)均高于B组患者(7.0%和55.8%,P<0.05);(2)A组患者治疗后生活质量改善情况优于B组患者(Z=-2.155,P=0.031);(3)A组患者骨髓抑制、胃肠道反应、末梢神经损害和放射性肺损伤发生率高于B组患者(P<0.05)。结论 3DCRT放射治疗同步L-OHP化疗能提高NSCLC患者病灶的近期控制率,但应做好对联合放化疗期间出现不良反应的对症处置。
Objective To investigate the clinical efficacy of 3-dimensional conformal radiotherapy (3DCRT) with concurrent orolipramine (L-OHP) chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 90 patients with localized NSCLC were randomly divided into group A (n = 47) and group B (n = 43). Patients in group B received 3DCRT radiotherapy. Patients in group A received simultaneous L-OHP Chemotherapy, compared two groups of patients after treatment of clinical efficacy and adverse reactions. Results The complete remission rate (10.6%) and total effective rate (78.7%) in group A were higher than those in group B (7.0% vs 55.8%, P <0.05). (2) The quality of life (3) The incidence of bone marrow suppression, gastrointestinal reaction, peripheral nerve injury and radiation-induced lung injury in group A was higher than that in group B (P <0.05), and the improvement was better than that in group B (Z = -2.155, P = 0.031) . Conclusions 3DCRT radiation therapy with synchronous L-OHP chemotherapy can improve the recent control rate of NSCLC lesions, but symptomatic treatment of adverse reactions during radiotherapy and chemotherapy should be done.